Centinel Spine recently announced significant expansion of coverage for lumbar TDR procedures in the Mid-Atlantic region of the U.S.
The policy expansion announced by New Jersey’s largest commercial payer—effective November 1, 2024—represents over 2.3 million covered lives across the state and includes a positive coverage recommendation for both one- and two-level lumbar TDR. Because prodisc L is the only lumbar TDR device with FDA approval for two-level use, the two-level coverage recommendation applies exclusively to the use of the prodisc L device.
Additionally, the largest commercial payer in the Philadelphia tri-state area has established positive coverage for both one- and two-level lumbar TDR. This policy expansion became effective October 20, 2024, and represents over 850,000 covered lives.
With this favorable coverage expansion in the Mid-Atlantic region, it is estimated that commercial coverage in the U.S. for one-level lumbar TDR has grown from 50% of covered lives in 2017 to nearly 95%* today. Commercial coverage in the U.S. for two-level lumbar TDR has made tremendous strides over the last two years, now with over 35% commercial coverage.
* Data on file, estimate based on combined positive and neutral policies.